Search
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Carindacillin
go.drugbank.com/drugs/DB09319ApprovedWithdrawnIt is no longer marketed in the United States.
Hepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnThere is no specific treatment for hepatitis.
trans NV-04
go.drugbank.com/drugs/DB05843Experimentaltrans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Synonyms: trans NV-04Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. … including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU
Products: STELARA 45mg/0.5mL Solution for Injection in Single-use VialPrednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approvedPrednisolone phosphate is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.
Mixtures: OFTALETYC® NFNV-07a
go.drugbank.com/drugs/DB05845ExperimentalNV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Mixtures: Mencevax Ac Pws 50mcg/vial, Mencevax Ac Pws 500mcg/vialTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]